#1 Clinical Trials Search in Europe

Basiliximab

Basiliximab, also known by its brand name Simulect, is a monoclonal antibody used in various clinical trials to prevent organ rejection and treat autoimmune conditions. This article explores the use of Basiliximab in different medical scenarios, including kidney transplantation, liver transplantation, ulcerative colitis, and graft-versus-host disease prevention. We’ll examine its effectiveness, safety profile, and potential benefits in comparison to other treatments.

Table of Contents

What is Basiliximab?

Basiliximab, also known by its brand name Simulect, is a medication used in the field of transplant medicine[1]. It belongs to a class of drugs called monoclonal antibodies, which are laboratory-produced molecules engineered to serve as substitute antibodies. These can enhance, mimic or restrain the immune system’s response to various conditions[3].

How Basiliximab Works

Basiliximab works by targeting a specific part of the immune system. It binds to the CD25 receptor, which is found on the surface of certain immune cells called T-cells. By attaching to this receptor, basiliximab blocks the action of interleukin-2, a substance that stimulates T-cell growth and activity. This helps to suppress the immune system’s response, which is crucial in preventing organ rejection after transplantation[3].

Conditions Treated with Basiliximab

Basiliximab is primarily used in the following medical situations:

  • Kidney Transplantation: It’s commonly used to prevent organ rejection in patients receiving a kidney transplant[1].
  • Liver Transplantation: Some studies have explored its use in liver transplant patients[7].
  • Ulcerative Colitis: Research has been conducted on its potential benefits for patients with moderate to severe ulcerative colitis, a type of inflammatory bowel disease[2].
  • Corneal Transplantation: It has been studied for use in high-risk corneal transplant patients[5].
  • Graft-versus-Host Disease (GVHD) Prevention: It’s being investigated for preventing GVHD in bone marrow transplant patients[3].

How Basiliximab is Administered

Basiliximab is typically administered intravenously (through a vein) in a hospital or clinical setting. The dosage and frequency can vary depending on the specific condition being treated and the individual patient’s needs. Here are some common administration protocols:

  • For kidney transplantation: Often given as two 20 mg doses, with the first dose given within 2 hours before transplantation surgery and the second dose 4 days after transplantation[9].
  • For ulcerative colitis studies: Some trials have used 40 mg doses given at baseline, week 2, and week 4[2].
  • For GVHD prevention: One study administered it on day 7 or 9 post-transplant, depending on the type of donor cells used[3].

Effectiveness of Basiliximab

The effectiveness of basiliximab has been demonstrated in various clinical settings:

  • In kidney transplantation, it has shown to be effective in reducing the risk of acute organ rejection when used as part of an immunosuppressive regimen[1].
  • Studies in ulcerative colitis have explored its potential to improve symptoms and induce remission in patients who haven’t responded well to other treatments[2].
  • In high-risk corneal transplantation, it has been compared to traditional immunosuppressants like cyclosporine for preventing graft rejection[5].
  • Research in liver transplantation has investigated its use in combination with other drugs to optimize immunosuppression while preserving renal function[7].

Potential Side Effects and Safety Considerations

As with any medication, basiliximab can cause side effects. Some potential side effects and safety considerations include:

  • Increased risk of infections: Because basiliximab suppresses the immune system, it can make patients more susceptible to various infections[9].
  • Allergic reactions: Some patients may experience allergic reactions to the drug[1].
  • Cardiovascular effects: There may be a risk of hypertension (high blood pressure) in some patients[1].
  • Gastrointestinal symptoms: Some patients may experience nausea, vomiting, or diarrhea[2].

It’s important to note that the benefits of basiliximab in preventing organ rejection or treating severe conditions often outweigh these potential risks. However, patients should always discuss any concerns with their healthcare provider.

Ongoing Research and Future Prospects

Research into basiliximab is ongoing, with several clinical trials exploring its potential in various medical fields:

  • Its use in umbilical cord blood transplantation for malignant hematologic diseases is being studied to reduce the incidence of severe acute GVHD[6].
  • Researchers are investigating its potential in preventing recurrence of IgA nephropathy after kidney transplantation[8].
  • Studies are comparing basiliximab to other immunosuppressive therapies in kidney transplantation to optimize treatment protocols[9].
  • Some researchers are exploring whether basiliximab can be safely omitted in certain well-matched living kidney transplant scenarios[10].

These ongoing studies aim to refine the use of basiliximab, potentially expanding its applications and improving patient outcomes in various transplant and autoimmune conditions.

Aspect Details
Primary Uses Prevention of organ rejection in transplantation (kidney, liver, corneal), treatment of ulcerative colitis, prevention of graft-versus-host disease
Administration Intravenous infusion, typically 20-40 mg doses
Mechanism of Action Targets CD25 receptor on activated T-cells, inhibiting T-cell proliferation
Potential Benefits Reduced organ rejection, improved graft survival, potential for lower doses of other immunosuppressants
Common Study Endpoints Incidence of acute rejection, graft survival, renal function, safety profile
Comparison Treatments Standard immunosuppression regimens, other monoclonal antibodies, antithymocyte globulin (ATG)
Safety Considerations Risk of infections, potential for allergic reactions, development of anti-drug antibodies

FAQ

  • What is Basiliximab and how does it work? Basiliximab is a monoclonal antibody that targets the CD25 receptor on activated T-cells. It works by inhibiting T-cell proliferation, which helps prevent organ rejection in transplant patients and can potentially reduce inflammation in autoimmune conditions.
  • In which medical conditions is Basiliximab being studied? Basiliximab is being studied in various conditions, including kidney transplantation, liver transplantation, ulcerative colitis, corneal transplantation, and prevention of graft-versus-host disease in bone marrow transplantation.
  • How is Basiliximab typically administered in clinical trials? In most trials, Basiliximab is administered intravenously. The dosage and frequency vary depending on the condition being treated, but common regimens include 20 mg doses on the day of transplant and 4 days after, or 40 mg doses given at regular intervals.
  • What are the potential benefits of using Basiliximab in transplantation? Potential benefits include reduced incidence of organ rejection, improved graft survival, and the possibility of using lower doses of other immunosuppressive medications, which may lead to fewer side effects.
  • Are there any known side effects or risks associated with Basiliximab use? While Basiliximab is generally well-tolerated, potential risks include increased susceptibility to infections, allergic reactions, and the possibility of developing antibodies against the drug. Specific side effects can vary depending on the condition being treated and individual patient factors.

Ongoing Clinical Trials on Basiliximab

  • Reduced Immunosuppression Therapy Trial for Elderly Kidney Transplant Recipients with End-Stage Renal Disease

    Recruiting

    1 1 1 1
    Investigated drugs:
    Spain

  • Study on Preventing Rejection in Kidney Transplant Patients Using Rabbit Anti-Human Thymocyte Immunoglobulin and Basiliximab

    Recruiting

    1 1 1 1
    Investigated drugs:
    France

  • Study on Optimizing Immunosuppressive Treatment for Living Donor Kidney Transplant Patients Using Prednisone, Basiliximab, and Tacrolimus Monohydrate

    Not yet recruiting

    1 1 1 1
    Investigated drugs:
    Spain

  • Study of tacrolimus, everolimus and mycophenolate mofetil combination in elderly patients after kidney transplant

    Not recruiting

    1 1 1 1
    Investigated drugs:
    Belgium The Netherlands

Glossary

  • Monoclonal antibody: A type of protein made in the laboratory that can bind to substances in the body, including cancer cells. Monoclonal antibodies are used to treat some types of cancer and other diseases.
  • CD25 receptor: A protein found on the surface of certain immune cells, particularly activated T-cells. It is part of the receptor for interleukin-2, a molecule important in T-cell activation and proliferation.
  • Graft-versus-host disease (GVHD): A complication that can occur after a bone marrow or stem cell transplant, where the donor's immune cells attack the recipient's tissues.
  • Acute rejection: A rapid immune response against a transplanted organ, typically occurring within the first few months after transplantation.
  • Immunosuppression: The partial or complete suppression of the immune response, often deliberately induced to prevent rejection of transplanted organs or to treat autoimmune diseases.
  • Ulcerative colitis: A chronic inflammatory bowel disease that affects the lining of the large intestine (colon) and rectum, causing inflammation and ulcers.
  • Glomerular filtration rate (GFR): A measure of how well the kidneys are filtering waste from the blood, used to assess kidney function.
  • Cyclosporine: An immunosuppressant drug commonly used to prevent organ rejection in transplant recipients.
  • Induction therapy: The initial treatment given at the start of a medical therapy, often more intensive than subsequent maintenance treatment.
  • Biopsy-proven acute rejection (BPAR): Rejection of a transplanted organ that has been confirmed through examination of a tissue sample (biopsy) from the organ.

References

  1. https://clinicaltrials.gov/study/NCT00928811
  2. https://clinicaltrials.gov/study/NCT00430898
  3. https://clinicaltrials.gov/study/NCT00975975
  4. https://clinicaltrials.gov/study/NCT01061996
  5. https://clinicaltrials.gov/study/NCT00409656
  6. https://clinicaltrials.gov/study/NCT06480630
  7. https://clinicaltrials.gov/study/NCT00343226
  8. https://clinicaltrials.gov/study/NCT02523768
  9. https://clinicaltrials.gov/study/NCT03006419
  10. https://clinicaltrials.gov/study/NCT02459977